Management of Incompatible Blood Transfusion

Clinical Decision Framework

In life-threatening situations where compatible blood is unavailable, the American Society of Hematology recommends transfusing the least incompatible blood available while simultaneously administering immunosuppressive therapy to mitigate hemolytic reactions, as the risk of death from severe anemia outweighs the risk of transfusion reaction 1, 2
Verify life-threatening anemia is present, defined as hemodynamic instability, altered mental status, cardiac ischemia, or imminent cardiovascular collapse that cannot be managed with supportive care alone, and engage a transfusion medicine specialist immediately for ongoing risk-benefit discussions 1, 2
The American Society of Hematology recommends starting immunosuppressive therapy prior to or concurrent with transfusion, based on very low certainty evidence but representing consensus expert opinion for rare, life-threatening scenarios 1, 2

ABO compatibility takes absolute priority, and never transfuse ABO-incompatible blood as this causes immediate, severe hemolysis with high mortality 3, 4
Monitor vital signs continuously, including heart rate, blood pressure, temperature, and respiratory rate every 15 minutes, and watch for signs of acute hemolytic reaction: tachycardia, hypotension, fever, hemoglobinuria, back pain 3, 4

Consider automated or manual red cell exchange instead of simple transfusion if the patient has high baseline hemoglobin that precludes simple transfusion, as this removes the patient's incompatible antibody-coated cells while providing oxygen-carrying capacity 1, 2

Obtain an extended red cell antigen profile (genotype preferred over phenotype) for patients likely to need multiple transfusions, and use extended antigen matching for all future transfusions to prevent additional alloimmunization 1, 2
Document shared decision-making discussions with the patient/family, weighing transfusion risks versus death from anemia, and inform the patient post-discharge about antibody development and implications for future transfusions 1, 2

Discontinue the blood product immediately at the first sign of a transfusion reaction (tachycardia, hypotension, fever, rash, breathlessness, hemoglobinuria) 5
Contact the transfusion laboratory immediately and return the blood product for investigation 5
Double-check all documentation to identify potential administration errors 5
Verify patient identification with four core identifiers (first name, last name, date of birth, patient ID number) before every transfusion 5
Check compatibility label against patient identification at bedside 5
Visually inspect blood products for discoloration, clots, or leakage 5

Antihistamines may be administered for allergic symptoms 5
Steroids may be given for severe reactions 5
Intramuscular or intravenous epinephrine if the reaction is life-threatening or anaphylactic 5
Consider prophylactic immunosuppression with IVIg, steroids, and/or rituximab before transfusion when compatible blood cannot be found for patients with sickle cell disease at high risk for acute hemolytic transfusion reaction 6, 7, 8, 9
IVIg: 0.4-1 g/kg/day for 3-5 days (up to total dose of 2 g/kg) 10
High-dose steroids: Methylprednisolone or prednisone 1-4 mg/kg/day 10
Rituximab: Primarily for prevention of additional alloantibody formation in patients requiring future transfusions 10

For high-risk patients with sickle cell disease, use extended antigen matching (C/c, E/e, K, Jka/Jkb, Fya/Fyb, S/s) to prevent alloimmunization 6, 8, 9